Skip to main content
SpringerLink
Log in

Time for Isoniazid Pharmacogenomic-Guided Therapy of Tuberculosis Based on NAT2 Acetylation Profiles in India

  • Current Opinion
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Abstract

Tuberculosis (TB), caused by a bacterial pathogen Mycobacterium tuberculosis, is a highly contagious infectious disease. India ranks top in TB burden among other countries in the world. The current treatment of TB in India includes isoniazid (INH) as the first-line drug, based on the “one dose fits all’’ concept. It is widely known that INH is not equally tolerated by all patients, as the metabolization process of INH is highly dependent on the acetylation profile of an individual based on the pharmacogenomic profile of the N-acetyltransferase (NAT2) gene. Also, several experimental studies in several TB endemic countries have established that redosing of INH based on genetic profiles of TB patients of the NAT2 can help in effective TB treatment and minimize adverse drug reactions (ADRs). Moreover, acetylation phenotype-based INH dosing has been shown to be cost-effective as well as successful in terms of treatment outcomes and the increase in the quality of life of the patients. Considering a genetically heterogenous population with high vulnerability to TB, we here argue that India could lead in establishing a pharmacogenomic-guided therapy (PGT) under the INH-NAT2 model. With such an approach, not only could an innovative step towards ‘End-TB’ by the year 2025 be taken but a personalized medicine approach for TB treatment be initiated in India, particularly in tribal communities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. WHO Global TB Report 2020. https://www.who.int/tb/publications/global_report/en/ . Accessed 20 Nov 2021.

  2. Thomas BE, Thiruvengadam K, Rani S, Gangadhar Rao V, Yadav R, Paluru V, Jacob Purthy A, Hussain T, Indira Krishna AK, Joseph A, Kumar BA. Understanding health care-seeking behaviour of the tribal population in India among those with presumptive TB symptoms. PLoS ONE. 2021;16(5):e0250971.

    Article  CAS  Google Scholar 

  3. Das A. Aiming for a tuberculosis-free India: perspective of a highly endemic Particularly Vulnerable Tribal Group (PVTG). Clin Epidemiol Global Health. 2021.

  4. Prakash R, Kumar D, Gupta VK, Jain S, Chauhan DS, Tiwari PK, Katoch VM. Status of multidrug resistant tuberculosis (MDR-TB) among the Sahariya tribe of North Central India. J Infect Public Health. 2016;9(3):289–97.

    Article  Google Scholar 

  5. Murray JF, Schraufnagel DE, Hopewell PC. Treatment of tuberculosis. A historical perspective. Ann Am Thoracic Soc. 2015;12(12):1749–59.

    Article  Google Scholar 

  6. Jhun BW, Koh WJ. Treatment of isoniazid-resistant pulmonary tuberculosis. Tuberc Respir Dis. 2020;83(1):20–30.

    Article  Google Scholar 

  7. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther. 2011;89(6):911–4.

    Article  CAS  Google Scholar 

  8. Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med. 2018;16(1):1.

    Article  Google Scholar 

  9. Guaoua S, Ratbi I, El Bouazzi O, Hammi S, Tebaa A, Bourkadi JE, Bencheikh RS, Sefiani A. NAT2 genotypes in Moroccan patients with hepatotoxicity due to antituberculosis drugs. Genet Test Mol Biomark. 2016;20(11):680–4.

    Article  CAS  Google Scholar 

  10. Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, Okuda Y, Takashima T, Kamimura S, Fujio Y, Kawase I. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013;69(5):1091–101.

    Article  CAS  Google Scholar 

  11. Chatterjee S, Poonawala H, Jain Y. Drug-resistant tuberculosis: is India ready for the challenge? BMJ Glob Health. 2018;3(4):e000971.

    Article  Google Scholar 

  12. Boelsterli UA, Lee KK. Mechanisms of isoniazid-induced idiosyncratic liver injury: Emerging role of mitochondrial stress. J Gastroenterol Hepatol. 2014;29(4):678–87.

    Article  CAS  Google Scholar 

  13. Patin E, Barreiro LB, Sabeti PC, Austerlitz F, Luca F, Sajantila A, Behar DM, Semino O, Sakuntabhai A, Guiso N, Gicquel B. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet. 2006;78(3):423–36.

    Article  CAS  Google Scholar 

  14. Windmill KF, Gaedigk A, de la Hall PM, Samaratunga H, Grant DM, McManus ME. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci. 2000;54(1):19–29.

    Article  CAS  Google Scholar 

  15. Khan N, Das A. Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular? Precis Clin Med. 2020;3(3):240–3.

    Article  Google Scholar 

  16. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS ONE. 2011;6(4):e18507.

    Article  CAS  Google Scholar 

  17. Khan N, Pande V, Das A. NAT2 sequence polymorphisms and acetylation profiles in Indians. Pharmacogenomics. 2013;14(3):289–303.

    Article  CAS  Google Scholar 

  18. Cordes H, Thiel C, Aschmann HE, Baier V, Blank LM, Kuepfer L. A physiologically based pharmacokinetic model of isoniazid and its application in individualizing tuberculosis chemotherapy. Antimicrob Agents Chemother. 2016;60(10):6134–45.

    Article  CAS  Google Scholar 

  19. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, Cascorbi I, Doroshyenko O, Sörgel F, Fuhr U. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005;49(5):1733–8.

    Article  CAS  Google Scholar 

  20. Mitchison DA, Davies G. The chemotherapy of tuberculosis: past, present and future [state of the art]. Int J Tuberc Lung Dis. 2012;16(6):724–32.

    Article  CAS  Google Scholar 

  21. Zabost A, Brzezińska S, Kozińska M, Błachnio M, Jagodziński J, Zwolska Z, Augustynowicz-Kopeć E. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients. Biomed Res Int. 2013;7:2013.

    Google Scholar 

  22. Jing W, Zong Z, Tang B, Wang J, Zhang T, Wen SA, Xue Y, Chu N, Zhao W, Huang H. Population pharmacokinetic analysis of isoniazid among pulmonary tuberculosis patients from China. Antimicrob Agents Chemother. 2020;64(3):e01736-e1819.

    Article  CAS  Google Scholar 

  23. Denti P, Jeremiah K, Chigutsa E, Faurholt-Jepsen D, PrayGod G, Range N, Castel S, Wiesner L, Hagen CM, Christiansen M, Changalucha J. Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania. PLoS ONE. 2015;10(10):e0141002.

    Article  Google Scholar 

  24. Smith T, Wolff KA, Nguyen L. Molecular biology of drug resistance in Mycobacterium tuberculosis. In: Pathogenesis of Mycobacterium tuberculosis and its interaction with the host organism. 2012;53–80.

  25. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathogens Global Health. 2015;109(7):309–18.

    Article  Google Scholar 

  26. Nguyen L. Antibiotic resistance mechanisms in Mycobacterium tuberculosis: an update. Arch Toxicol. 2016;90(7):1585–604.

    Article  CAS  Google Scholar 

  27. Ali MH, Alrasheedy AA, Kibuule D, Hassali MA, Godman B, Abdelwahab MF, Abbadi RY. Isoniazid acetylation phenotypes in the Sudanese population; findings and implications. J Clin Tuberc Other Mycobacter Dis. 2019;17:100120.

    Article  Google Scholar 

  28. Verma R, Patil S, Zhang N, Moreira FMF, Vitorio MT, Santos ADS, Wallace E, Gnanashanmugam D, Persing DH, Savic RM, Croda J, Andrews JR. A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosing for tuberculosis treatment. Am J Respir Crit Care Med. 2021;204(11):1317–26.

    Article  CAS  Google Scholar 

  29. Rens NE, Uyl-de Groot CA, Goldhaber-Fiebert JD, Croda J, Andrews JR. Cost-effectiveness of a pharmacogenomic test for stratified isoniazid dosing in treatment of active tuberculosis. Clin Infect Dis. 2020;71(12):3136–43.

    Article  Google Scholar 

  30. Charan AS, Gupta N, Dixit R, Arora P, Patni T, Antony K, Singh M. Pattern of InhA and KatG mutations in isoniazid monoresistant Mycobacterium tuberculosis isolates. Lung India. 2020;37(3):227.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank the Director General Indian Council of Medical Research, New Delhi for providing facilities and support. The authors thank two anonymous reviewers and the editor whose suggestions have helped immensely in making the manuscript focused and clear.

Author information

Authors and Affiliations

  1. Genomic Epidemiology Laboratory, ICMR-National Institute of Research in Tribal Health, Nagpur Road, Garha, Jabalpur, 482003, India

    Nikhat Khan & Aparup Das

Authors
  1. Nikhat Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aparup Das
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aparup Das.

Ethics declarations

Funding

No source of funding was received to prepare this article.

Conflict of interest

The authors have no conflict of interest to declare.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Authors contributions

Nikhat Khan has conceptualized the study, conducted literature survey, prepared the figure and written the initial version of the manuscript. Aparup Das has jointly conceptualized the study, conducted additional literature survey and written the final version of the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khan, N., Das, A. Time for Isoniazid Pharmacogenomic-Guided Therapy of Tuberculosis Based on NAT2 Acetylation Profiles in India. Eur J Drug Metab Pharmacokinet 47, 443–447 (2022). https://doi.org/10.1007/s13318-022-00764-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13318-022-00764-x

Search

Navigation